NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · COR · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cencora, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Cencora, Inc.’s forward annual dividend is $2.40 per share, paid quarterly. The forward yield is 0.73% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Cencora, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $4.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cencora, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| May 7, 2025 |
| $4.42+7.54% vs estimate |
| $75.45B-0.3% vs estimate |
| Q1 2025 | Feb 5, 2025 | $3.73+6.57% vs estimate | $81.49B+4.06% vs estimate |
|---|
| Q4 2024 | Nov 6, 2024 | $3.34+3.41% vs estimate | $79.05B+1.84% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
46 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $350.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$980.88+$20.32 (+2.12%)
McKesson Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.79% below the high.
$251.09+$6.33 (+2.59%)
Cardinal Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
$86.44+$1.48 (+1.74%)
Henry Schein, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.23% below the high.
CN¥16.47+CN¥0.04 (+0.24%)
Shanghai Pharmaceuticals Holding Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 11.26% below the high.
HK$16.22+HK$0.30 (+1.88%)
Sinopharm Group Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.39% below the high.
